FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to a method for determining a response to an anti-oestrogen therapy in the individuals suffering diagnosed breast cancer. Substance of the method for determining the response to the anti-oestrogen therapy in the individual suffering breast cancer consists in calculating an endocrine therapeutic index of circulating immune complexes (ETI-COC). If the ETI-COC falls within the range of 0-3, the favourable response to the anti-oestrogen therapy is stated, while the value of 4-6 shows the moderate response, and the value of 7-14 indicates the weak response.
EFFECT: using declared method enables determining the individual's response to the anti-oestrogen therapy effectively.
10 cl, 7 tbl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NON-INVASIVE DIAGNOSIS BY SEQUENCING OF 5-HYDROXYMETHYLATED CELL-FREE DNA | 2017 |
|
RU2742355C2 |
| CANCER DETECTION BY HIGH BCL-2 LEVELS | 2007 |
|
RU2436098C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| DIRECT CAPTURE, AMPLIFICATION AND SEQUENCING OF TARGET DNA USING IMMOBILISED PRIMERS | 2011 |
|
RU2565550C2 |
| REPRESENTATIVE DIAGNOSIS | 2016 |
|
RU2743169C2 |
| METHODS AND DEVICES FOR DETECTION AND IDENTIFICATION OF ENCODED GRANULES AND BIOLOGICAL MOLECULES | 2007 |
|
RU2487169C2 |
| PRIMERS AND PROBES FOR POLYMERASE CHAIN REACTION FOR DETECTING MYCOBACTERIUM TUBERCULOSIS | 2015 |
|
RU2717655C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
